AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of “Buy” by Analysts

AtriCure, Inc. (NASDAQ:ATRC) has earned a consensus rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $50.8889.

ATRC has been the subject of a number of research analyst reports. Needham & Company LLC lifted their price target on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, July 30th. Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. UBS Group dropped their price target on shares of AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. BTIG Research set a $54.00 price objective on shares of AtriCure in a report on Wednesday, July 30th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $60.00 price objective on shares of AtriCure in a report on Wednesday, April 30th.

Insiders Place Their Bets

In other AtriCure news, insider Vinayak Doraiswamy sold 2,500 shares of AtriCure stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total value of $91,450.00. Following the completion of the transaction, the insider owned 71,872 shares of the company’s stock, valued at $2,629,077.76. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Regina E. Groves sold 2,452 shares of AtriCure stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $36.82, for a total transaction of $90,282.64. Following the completion of the transaction, the director directly owned 33,715 shares of the company’s stock, valued at approximately $1,241,386.30. This represents a 6.78% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,452 shares of company stock valued at $445,333 over the last 90 days. 3.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On AtriCure

Hedge funds have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. acquired a new position in AtriCure in the second quarter worth $37,000. First Horizon Advisors Inc. boosted its holdings in shares of AtriCure by 135.3% during the first quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company’s stock valued at $47,000 after acquiring an additional 832 shares during the period. Johnson Financial Group Inc. boosted its holdings in shares of AtriCure by 1,184.1% during the fourth quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company’s stock valued at $49,000 after acquiring an additional 1,492 shares during the period. US Bancorp DE boosted its holdings in shares of AtriCure by 98.1% during the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company’s stock valued at $51,000 after acquiring an additional 789 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in shares of AtriCure during the fourth quarter valued at $60,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Down 0.9%

Shares of NASDAQ:ATRC opened at $35.73 on Friday. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. The company has a fifty day simple moving average of $32.93 and a 200 day simple moving average of $33.95. The firm has a market cap of $1.78 billion, a PE ratio of -46.40 and a beta of 1.61. AtriCure has a 12-month low of $23.97 and a 12-month high of $43.11.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.13. The business had revenue of $136.14 million during the quarter, compared to analyst estimates of $130.17 million. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The business’s revenue was up 17.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS. On average, equities research analysts anticipate that AtriCure will post -0.6 EPS for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.